AstraZeneca posts 76% efficacy in latest U.S. trial

25.03.2021 - Evdokimov Roman
AstraZeneca posts 76% efficacy in latest U.S. trial

Based on the new analysis of its U.S. trial, AstraZeneca recorded a 76% efficacy rate, slightly lower in the previous efficacy outing reported this week which drew criticisms for using outdated data.

Monday’s AstraZeneca data reported a 79% efficacy rate but excluded more recent COVID-19 cases, a case that saw U.S. health officials in outrage.

The new and more accurate efficacy rate recorded in the latest study will heavily impact the decision to grant U.S. emergency use authorization of the vaccine.

Moreover, AstraZeneca stressed that the Oxford University-developed vaccine had a 100% efficacy rate against severe cases of contagious disease.

The new efficacy rate was lifted from 190 infections among over 32,000 participants in the U.S., Peru, and Chile while the previous data came from the study of 141 cases through Feb. 17.

AstraZeneca also reported that the vaccine was 85% effective in people aged 65 and above, higher than the 80% previously reported.

 

Risk disclaimer "PROMETHEUS LTD – Trust Company Complex, Ajeltake Road, Ajeltake Island, Majuro, Republic of the Marshall Islands MH96960 is a financial services institution outside the European Union Area, which is subject to the supervision of the IFMRRC Certificate 0395 AA V0155 Trading in Forex/ CFDs and Other Derivatives is highly speculative and carries a high level of risk. It is possible to lose all your capital. 70% of trading deals can be unprofitable. These products may not be suitable for everyone and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. This Website may contain information in particular regarding financial services and products that could be regarded b a E.U. supervisory authority as an offer of financial services targeted in Europe. ESMA intervention measures do not apply to customers of PROMETHEUS LTD and it is your responsibility to choose a company which is most suitable for your trading needs. By clicking continue you confirm that you have read, understood and agree to the risk disclosures, terms of service, cash policies, privacy policies and this notice and that you are visiting this website on your own initiative, without any encouragement whatsoever from umarkets.ai or PROMETHEUS LTD." Cookies notification: We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we assume that you are happy with it. Read more. Continue
×

Help with deposit?